4:20 pm : Concerns over inflation, Fed tightening, Iran, earnings growth, and the yield curve continue to hang over the equity market, but investors found reasons to buy today. Cisco (CSCO 19.44 +1.35) delivered better than expected earnings after yesterday's close, and news that Pfizer (PFE 26.44 +1.50) may divest its lower-margin consumer health care business lent further upside. In addition, the market took a bullish cue from extended price declines across the energy complex.
The notion that Cisco did not disappoint, as has been the case with a number of Tech companies
Buying the Best Grains. Keep in mind that breads, crackers, grains, pastas and rice are all naturally low in fat; check labels to make sure the products you buy are as well. If total fat exceeds 2 - 3 grams per serving, some ingredient was added that you don't want.
More
JESSICA'S DIVA DEMANDS
Jessica Simpson, 25, likes to act clueless, but she can swing her celebrity weight like a pro. According to a studio source, weeks before the press tour for The Dukes of Hazzard began, "we were bombarded with a six-page pamphlet of demands for Jessica from the office of her dad, Joe Simpson." Among Jessica's requests: paid accommodations for her hairstylist and assistant in the same hotel as Jessica; a wardrobe budget estimated in the thousands of dollars; cases of Evian water; and paid private... •JEN FREAKS OVER ANGELINA'S NEW BABY •JULIA STILES, GWYNETH PALTROW AND MORE!
Security scare forces US Capitol evacuation Workers in yellow hazardous materials suits enter the Russell Senate Office Building in Washington February 8, 2006. (Jonathan Ernst/Reuters)
2:23 pm PT Willis Group reports in-line; boosts dividend 9% to $0.94 (WSH) : Reports Q4 (Dec) earnings of $0.38 per share, in-line with the Reuters Estimates consensus of $0.38; revenues fell 4.4% year/year to $562 mln vs the $577.5 mln consensus.
2:16 pm PT Gibraltar Industries beats by $0.09, ex items; guides (ROCK) : Reports Q4 (Dec) earnings of $0.41 per share, excluding non-recurring items, $0.09 better than the Reuters Estimates consensus of $0.32; revenues rose 30.9% year/year to $334 mln vs the $316.2 mln consensus. Co guides for Q1, sees EPS of $0.40-0.45 vs. $0.45 consensus.
2:08 pm PT AstraZeneca: New England Journal of Medicine publishes NXY-059 study (AZN) 46.33 -0.47 : Co and Renovis (RNVS) announces that results from the SAINT I trial,� were published today in the New England Journal of Medicine, report the effect of AZN's investigational drug, NXY-059, intended for the treatment of acute ischemic stroke. The data showed a statistically significant reduction with NXY- 059 versus placebo on the primary outcome of stroke-related disability, as assessed on the Modified Rankin Scale. Additional analysis of the data showed a reduction in the disability of patients at both ends of the scale, with 4.4% more patients treated with NXY-059 becoming free of symptoms and 3.7% more patients able to walk without help and being less dependent on others for bodily needs, compared to placebo. NXY-059 did not significantly improve neurological function as measured in the pre-specified analysis of SAINT I data on the NIH stroke scale.Mortality was unaffected by treatment with NXY-059 compared with placebo. The most common adverse events for NXY-059 in the study were fever, headache, urinary tract infection, stroke in evolution, and hypokalemia.
Add Content
Change Layout
Change Colors
New mail
